Patterns of Pharmacogenetic Diversity in African Populations: Role of Ancient and Recent History

• Cheok MH , LugthartS, EvansWE: Pharmacogenomics of acute leukemia.Annu. Rev. Pharmacol. Toxicol.46 , 317–353 (2006).
   PubMed Web of Science ®Google Scholar
• Sgaier SK , JhaP, MonyP et al.: Public health. Biobanks in developing countries: needs and feasibility.Science318(5853) , 1074–1075 (2007).
   PubMed Web of Science ®Google Scholar
• Matimba A , OlukaM, EbeshiBU et al.: Establishment of a biobank and pharmacogenetics database of African populations.Eur. J. Hum. Genet.16(7) , 780–783 (2008).
   PubMed Web of Science ®Google Scholar
• Tishkoff SA , VerrelliB: Patterns of human genetic diversity: implications for human evolutionary history and disease.Annu. Rev. Genomics. Hum. Genet.4 , 293–340 (2003).
   PubMed Web of Science ®Google Scholar
• Oliveira E , MarshS, van Booven DJ, Amorim A, Prata MJ, McLeod HL: Pharmacogenetically relevant polymorphisms in Portugal. Pharmacogenomics8(7) , 703–712 (2007).
   PubMed Web of Science ®Google Scholar
• Excoffier L , LavalG, SchneiderS: Arlequin ver. 3.0: An integrated software package for population genetics data analysis.Evol. Bioinform. Online1 , 47–50 (2005).
   PubMed Web of Science ®Google Scholar
• Bertorelle G , ExcoffierL: Inferring admixture proportions from molecular data.Mol. Biol. Evol.15(10) , 1298–1311 (1998).
   PubMed Web of Science ®Google Scholar
• Falush D , StephensM, PritchardJK: Inference of population structure using multilocus genotype data: dominant markers and null alleles.Mol. Ecol. Notes7(4) , 574–578 (2007).
   PubMed Web of Science ®Google Scholar
• Pritchard JK , StephensM, DonnellyP: Inference of population structure using multilocus genotype data.Genetics155(2) , 945–959 (2000).
   PubMed Web of Science ®Google Scholar
• Takeuchi F , McGinnisR, BourgeoisS et al.: A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.PLoS Genet.5(3) , E1000433 (2009)
   PubMed Web of Science ®Google Scholar
• Pearce CL , NearAM, van den Berg DJ et al.: Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. Br. J. Cancer.100(2) , 412–420 (2009).
   PubMed Web of Science ®Google Scholar
• Gurwitz D , ZikaE, HopkinsMM, GaisserS, IbarretaD: Pharmacogenetics in Europe: barriers and opportunities.Public Health Genomics12(3) , 134–141 (2009).
   PubMed Web of Science ®Google Scholar
• Wilson JF , WealeME, SmithAC et al.: Population genetic structure of variable drug response.Nat. Genet.29(3) , 265–269 (2001).
   PubMed Web of Science ®Google Scholar
• Trovoada MJ , PereiraL, GusmãoL, AbadeA, AmorimA, PrataMJ: Pattern of mtDNA variation in three populations from São Tomé e Príncipe.Ann. Hum. Genet.68 , 40–54 (2004).
   PubMed Web of Science ®Google Scholar
• Trovoada MJ , TavaresL, GusmãoL et al.: Dissecting the genetic history of São Tomé e Príncipe: a new window from Y-chromosome biallelic markers.Ann. Hum. Genet.71 , 77–85 (2007).
   PubMed Web of Science ®Google Scholar
• Beleza S , GusmãoL, AmorimA, CarracedoA, SalasA: The genetic legacy of western Bantu migrations.Hum. Genet.117 , 366–375 (2005).
   PubMed Web of Science ®Google Scholar
• Pereira L , GusmãoL, AlvesC, AmorimA, PrataMJ: Bantu and European Y-lineages in sub-Saharan Africa.Ann. Hum. Genet.66 , 369–378 (2002).
   PubMed Web of Science ®Google Scholar
• Reiner AP , ZivE, LindDL, NevergeltCM et al.: Population structure, admixture, and aging-related phenotypes in African American adults: The Cardiovascular Health Study.Am. J. Hum. Genet.76 , 463–477 (2005).
   PubMed Web of Science ®Google Scholar
• Suarez-Kurtz G , PenaS: Pharmacogenomics in the Americas: the impact of genetic admixture.Curr. Drug Targets7(12) , 1649–1658 (2006).
   PubMed Web of Science ®Google Scholar
• Allabi A , GalaJL, DesagerJP, HeusterspreuteM, HorsmansY: Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.Br. J. Clin. Pharmacol.56(6) , 653–657 (2003)
   PubMed Web of Science ®Google Scholar
• Dorado P , BereczR, NorbertoMJ, YasarA, DahlML, LlerenaA: CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers.Eur. J. Clin. Pharmacol.59(3) , 221–225 (2003).
   PubMed Web of Science ®Google Scholar
• Yang J , MorinS, VerstuyftC et al.: Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations.Fund. Clin. Pharmacol.17(3) , 373–376 (2003).
   PubMed Web of Science ®Google Scholar
• Kimura M , IeiriI, MamiyaK, UraeA, HiguchiS: Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population.Ther. Drug. Monit.20(3) , 243–247 (1998).
   PubMed Web of Science ®Google Scholar
• Zeigler-Johnson C , WalkerA, ManckeB et al.: Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4.Hum. Hered.54(1) , 13–21 (2002).
   PubMed Web of Science ®Google Scholar
• van Schaik R , De Wildt S, van Iperen N, Uitterlinden A, van den Anker J, Lindemans J: CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. Clin. Chem.46(11) , 1834–1836 (2000).
   PubMed Web of Science ®Google Scholar
• Gervasini G , VizcainoS, GasibaC, CarrilloJA, BenitezJ: Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and other Caucasian populations.Ther. Drug Monit.27(6) , 819–821 (2005).
   PubMed Web of Science ®Google Scholar
• Naoe T , TakeyamaK, YokozawaT et al.: Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia.Clin. Cancer Res.6(10) , 4091–4095 (2000).
   PubMed Web of Science ®Google Scholar
• Ball SE , ScatinaJ, KaoJ et al.: Population distribution and effects on drug metabolism of a genetic variant in the 5´ promoter region of CYP3A4.Clin. Pharmacol. Ther.66(3) , 288–294 (1999).
   PubMed Web of Science ®Google Scholar
• Thompson E , Kuttab-BoulosH, WitonskyD, YangL, RoeB, Di Rienzo A: CYP3A variation and the evolution of salt-sensitivity variants. Am. J. Hum. Genet.75(6) , 1059–1069 (2004).
   PubMed Web of Science ®Google Scholar
• Anglicheau D , ThervetE, EtienneI et al.: CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.Clin. Pharmacol. Ther.75(5) , 422–433 (2004).
   PubMed Web of Science ®Google Scholar
• Allabi A , HorsmansY, IssaouiB, GalaJL: Single nucleotide polymorphisms of ABCB1 (MDR1) gene and distinct haplotype profile in a West Black African population.Eur. J. Clin. Pharmacol.61(2) , 97–102 (2005).
   PubMed Web of Science ®Google Scholar
• Lotsch J , SkarkeC, GeisslingerG: Simultaneous screening for three mutations in the ABCB1 gene.Genomics82(5) , 503–510 (2003).
   PubMed Web of Science ®Google Scholar
• Komoto C , NakamuraT, SakaedaT et al.: MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer.Drug Metab. Pharmacokinet.21(2) , 126–132 (2006).
   PubMed Web of Science ®Google Scholar
• Tang K , WongL, LeeE, ChongS, LeeC: Genomic evidence for recent positive selection at the human MDR1 gene locus.Hum. Mol. Genet.13(8) , 783–797 (2004).
   PubMed Web of Science ®Google Scholar
• Furuno T , LandiM, CeroniM et al.: Expression polymorphism of the blood–brain barrier component P-glycoprotein (MDR1) in relation to Parkinson‘s disease.Pharmacogenetics12(7) , 529–534 (2002).
   PubMedGoogle Scholar

▪ Website

• StatSoft Ltd www.statsoft.com
   Google Scholar